Log in
NASDAQ:MNTA

Momenta Pharmaceuticals Short Interest Ratio and Short Volume

$52.48
0.00 (0.00 %)
(As of 10/2/2020)
Add
Compare
Today's Range
$52.48
Now: $52.48
$52.48
50-Day Range
$52.08
MA: $52.38
$52.49
52-Week Range
$12.21
Now: $52.48
$52.53
VolumeN/A
Average Volume1.94 million shs
Market Capitalization$6.25 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.71

Short Interest

Momenta Pharmaceuticals (NASDAQ:MNTA) Short Interest Data

Current Short Volume:5,410,000 shares
Previous Short Volume:4,400,000 shares
Change Vs. Previous Month:+22.95%
Dollar Volume Sold Short:$283.48 million
Short Interest Ratio / Days to Cover:2.0
Last Record Date:September, 15 2020
Outstanding Shares:98,610,000 shares
Short Percent of Float:0.00%
Today's Trading Volume:0 shares
Average Trading Volume:1,939,894 shares
Today's Volume Vs. Average:-100.00%



Momenta Pharmaceuticals (NASDAQ:MNTA) Short Interest History

DateShares Sold ShortDollar Volume Sold ShortPercentage ChangePercentage FloatDays to CoverPrice on Record Date
9/15/20205,410,000 $283.48 million 23.0%0.0%1.7$52.40
8/31/20204,400,000 $229.55 million -35.3%0.0%1.5$52.17
8/14/20206,800,000 $354.62 million 6.6%0.0%2.8$52.15
7/31/20206,380,000 $189.10 million -5.6%0.0%5.5$29.64
7/15/20206,760,000 $199.35 million -17.1%0.0%6.1$29.49
6/30/20208,150,000 $244.50 million 31.7%0.0%7$30.00
6/15/20206,190,000 $197.28 million 0.0%0.0%5.5$31.87
5/29/20206,190,000 $233.61 million 51.7%0.0%5.7$37.74
5/15/20204,080,000 $128.44 million 15.6%0.0%3.5$31.48
4/30/20203,530,000 $115.04 million -12.0%0.0%3.1$32.59
4/15/20204,010,000 $137.54 million 12.6%0.0%3.5$34.30
3/31/20203,560,000 $114.13 million 4.1%0.0%2.7$32.06
3/13/20203,419,100 $101.72 million 2.4%0.0%3.1$29.75
2/28/20203,340,000 $81.76 million -10.0%0.0%2.5$24.48
2/14/20203,710,000 $108.15 million -10.6%0.0%2.9$29.15
1/31/20204,150,000 $127.49 million -20.4%0.0%3.5$30.72
1/15/20205,210,000 $165.42 million -7.8%0.0%4.6$31.75
12/31/20195,650,000 $159.22 million 19.2%0.0%6.2$28.18
11/29/20194,320,000 $67.87 million 2.6%4.4%8$15.71

Momenta Pharmaceuticals (NASDAQ:MNTA) Short Interest FAQ

speech bubbles
speech bubbles











What is Momenta Pharmaceuticals' current short interest?

Short interest is the volume of Momenta Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of September 15th, traders have sold 5,410,000 shares of MNTA short. 0.00% of Momenta Pharmaceuticals' shares are currently sold short. View details.

What is a good short interest ratio for Momenta Pharmaceuticals?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. Momenta Pharmaceuticals currently has a short interest ratio of 2.0.

Is Momenta Pharmaceuticals' short interest increasing or decreasing?

Momenta Pharmaceuticals saw a increase in short interest in September. As of September 15th, there was short interest totaling 5,410,000 shares, an increase of 23.0% from the previous total of 4,400,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does Momenta Pharmaceuticals' short interest compare to its competitors?

0.00% of Momenta Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the sub-industry of "biotechnology" compare to Momenta Pharmaceuticals: Amgen Inc. (1.16%), Gilead Sciences, Inc. (1.44%), Regeneron Pharmaceuticals, Inc. (1.57%), Vertex Pharmaceuticals Incorporated (0.00%), Biogen Inc. (2.33%), Seagen Inc. (0.00%), Alexion Pharmaceuticals, Inc. (2.33%), Immunomedics, Inc. (0.00%), Incyte Co. (0.00%), and Exact Sciences Co. (0.00%).

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications Inc ($5.17 billion), Aon PLC ($3.57 billion), ViacomCBS Inc. ($3.01 billion), Clorox Co ($2.91 billion), The Charles Schwab Co. ($2.80 billion), Mercadolibre Inc ($2.33 billion), Analog Devices, Inc. ($2.14 billion), Kroger Co ($1.99 billion), Moderna, Inc. ($1.96 billion), and Simon Property Group, Inc. ($1.80 billion). View all of the most shorted stocks.

What does it mean to sell short Momenta Pharmaceuticals stock?

Short selling MNTA is an investing strategy that aims to generate trading profit from Momenta Pharmaceuticals as its price is falling. To short Momenta Pharmaceuticals stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that Momenta Pharmaceuticals will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Momenta Pharmaceuticals?

A short squeeze for Momenta Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of MNTA, which in turn drives the price of the stock up even further.

How often is Momenta Pharmaceuticals' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including MNTA, twice per month. The most recent reporting period available is September, 15 2020.


This page was last updated on 10/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.